nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—Isoetarine—Salbutamol—chronic obstructive pulmonary disease	0.129	0.178	CrCrCtD
L-DOPA—Norepinephrine—Salbutamol—chronic obstructive pulmonary disease	0.12	0.166	CrCrCtD
L-DOPA—Levonordefrin—Salbutamol—chronic obstructive pulmonary disease	0.113	0.156	CrCrCtD
L-DOPA—Isoprenaline—Formoterol—chronic obstructive pulmonary disease	0.0975	0.135	CrCrCtD
L-DOPA—Isoprenaline—Arformoterol—chronic obstructive pulmonary disease	0.0975	0.135	CrCrCtD
L-DOPA—Epinephrine—Salbutamol—chronic obstructive pulmonary disease	0.0908	0.126	CrCrCtD
L-DOPA—Isoprenaline—Salbutamol—chronic obstructive pulmonary disease	0.0739	0.102	CrCrCtD
L-DOPA—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0203	0.346	CbGbCtD
L-DOPA—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0203	0.346	CbGbCtD
L-DOPA—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0181	0.308	CbGbCtD
L-DOPA—PSIP1—bronchus—chronic obstructive pulmonary disease	0.00207	0.13	CbGeAlD
L-DOPA—PSIP1—trachea—chronic obstructive pulmonary disease	0.00186	0.117	CbGeAlD
L-DOPA—DDC—respiratory system—chronic obstructive pulmonary disease	0.00143	0.0899	CbGeAlD
L-DOPA—PSIP1—lung—chronic obstructive pulmonary disease	0.00133	0.0837	CbGeAlD
L-DOPA—SLC7A5—respiratory system—chronic obstructive pulmonary disease	0.00128	0.0805	CbGeAlD
L-DOPA—SLC7A5—connective tissue—chronic obstructive pulmonary disease	0.00113	0.0709	CbGeAlD
L-DOPA—SLC7A5—bronchus—chronic obstructive pulmonary disease	0.00106	0.0663	CbGeAlD
L-DOPA—SLC7A5—smooth muscle tissue—chronic obstructive pulmonary disease	0.00103	0.0649	CbGeAlD
L-DOPA—SLC7A5—trachea—chronic obstructive pulmonary disease	0.000948	0.0595	CbGeAlD
L-DOPA—SLC7A8—lung—chronic obstructive pulmonary disease	0.000878	0.0552	CbGeAlD
L-DOPA—SLC7A5—Desoximetasone—Prednisone—chronic obstructive pulmonary disease	0.000833	0.506	CbGdCrCtD
L-DOPA—SLC7A5—Desoximetasone—Prednisolone—chronic obstructive pulmonary disease	0.000813	0.494	CbGdCrCtD
L-DOPA—Aminosalicylic Acid—MPO—chronic obstructive pulmonary disease	0.000775	0.162	CrCbGaD
L-DOPA—DDC—lung—chronic obstructive pulmonary disease	0.00076	0.0477	CbGeAlD
L-DOPA—Isoetarine—ADRB2—chronic obstructive pulmonary disease	0.000702	0.147	CrCbGaD
L-DOPA—SLC7A5—lung—chronic obstructive pulmonary disease	0.000681	0.0428	CbGeAlD
L-DOPA—DRD2—respiratory system—chronic obstructive pulmonary disease	0.000621	0.039	CbGeAlD
L-DOPA—Mesalazine—MPO—chronic obstructive pulmonary disease	0.000608	0.127	CrCbGaD
L-DOPA—SLC16A10—lung—chronic obstructive pulmonary disease	0.000521	0.0327	CbGeAlD
L-DOPA—DRD2—lung—chronic obstructive pulmonary disease	0.00033	0.0207	CbGeAlD
L-DOPA—Droxidopa—ADRB2—chronic obstructive pulmonary disease	0.000321	0.0672	CrCbGaD
L-DOPA—Isoprenaline—ADRB2—chronic obstructive pulmonary disease	0.000291	0.0611	CrCbGaD
L-DOPA—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000288	0.00202	CcSEcCtD
L-DOPA—Malaise—Formoterol—chronic obstructive pulmonary disease	0.000286	0.00201	CcSEcCtD
L-DOPA—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.000286	0.00201	CcSEcCtD
L-DOPA—Hiccups—Prednisone—chronic obstructive pulmonary disease	0.000286	0.00201	CcSEcCtD
L-DOPA—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000286	0.00201	CcSEcCtD
L-DOPA—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000284	0.002	CcSEcCtD
L-DOPA—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000283	0.00199	CcSEcCtD
L-DOPA—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000281	0.00197	CcSEcCtD
L-DOPA—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.00028	0.00197	CcSEcCtD
L-DOPA—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.00028	0.00197	CcSEcCtD
L-DOPA—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000278	0.00196	CcSEcCtD
L-DOPA—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.000278	0.00195	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000277	0.00195	CcSEcCtD
L-DOPA—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000277	0.00195	CcSEcCtD
L-DOPA—Cough—Formoterol—chronic obstructive pulmonary disease	0.000277	0.00195	CcSEcCtD
L-DOPA—Epinephrine—TNF—chronic obstructive pulmonary disease	0.000276	0.0579	CrCbGaD
L-DOPA—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000275	0.00194	CcSEcCtD
L-DOPA—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000275	0.00193	CcSEcCtD
L-DOPA—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000274	0.00193	CcSEcCtD
L-DOPA—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000274	0.00193	CcSEcCtD
L-DOPA—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000274	0.00193	CcSEcCtD
L-DOPA—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000274	0.00192	CcSEcCtD
L-DOPA—Cough—Montelukast—chronic obstructive pulmonary disease	0.000271	0.00191	CcSEcCtD
L-DOPA—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.00027	0.0019	CcSEcCtD
L-DOPA—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.00027	0.0019	CcSEcCtD
L-DOPA—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.00027	0.0019	CcSEcCtD
L-DOPA—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.00027	0.0019	CcSEcCtD
L-DOPA—Norepinephrine—ADRB2—chronic obstructive pulmonary disease	0.00027	0.0565	CrCbGaD
L-DOPA—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000269	0.00189	CcSEcCtD
L-DOPA—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000269	0.00189	CcSEcCtD
L-DOPA—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000269	0.00189	CcSEcCtD
L-DOPA—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000269	0.00189	CcSEcCtD
L-DOPA—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000269	0.00189	CcSEcCtD
L-DOPA—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000267	0.00188	CcSEcCtD
L-DOPA—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000267	0.00188	CcSEcCtD
L-DOPA—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000265	0.00186	CcSEcCtD
L-DOPA—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000264	0.00186	CcSEcCtD
L-DOPA—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000264	0.00186	CcSEcCtD
L-DOPA—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000264	0.00185	CcSEcCtD
L-DOPA—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000263	0.00185	CcSEcCtD
L-DOPA—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000262	0.00184	CcSEcCtD
L-DOPA—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000261	0.00184	CcSEcCtD
L-DOPA—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000259	0.00182	CcSEcCtD
L-DOPA—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000259	0.00182	CcSEcCtD
L-DOPA—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000259	0.00182	CcSEcCtD
L-DOPA—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000255	0.00179	CcSEcCtD
L-DOPA—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000255	0.00179	CcSEcCtD
L-DOPA—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000254	0.00179	CcSEcCtD
L-DOPA—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000254	0.00178	CcSEcCtD
L-DOPA—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000254	0.00178	CcSEcCtD
L-DOPA—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000252	0.00177	CcSEcCtD
L-DOPA—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000251	0.00176	CcSEcCtD
L-DOPA—Isoprenaline—CYP1A1—chronic obstructive pulmonary disease	0.00025	0.0524	CrCbGaD
L-DOPA—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.00025	0.00175	CcSEcCtD
L-DOPA—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	0.000249	0.00175	CcSEcCtD
L-DOPA—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000248	0.00175	CcSEcCtD
L-DOPA—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.000245	0.00173	CcSEcCtD
L-DOPA—Epinephrine—ADRB2—chronic obstructive pulmonary disease	0.000245	0.0513	CrCbGaD
L-DOPA—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000245	0.00172	CcSEcCtD
L-DOPA—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000242	0.0017	CcSEcCtD
L-DOPA—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000242	0.0017	CcSEcCtD
L-DOPA—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000241	0.00169	CcSEcCtD
L-DOPA—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000241	0.00169	CcSEcCtD
L-DOPA—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	0.00024	0.00169	CcSEcCtD
L-DOPA—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000236	0.00166	CcSEcCtD
L-DOPA—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000236	0.00166	CcSEcCtD
L-DOPA—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000234	0.00165	CcSEcCtD
L-DOPA—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000234	0.00165	CcSEcCtD
L-DOPA—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000233	0.00164	CcSEcCtD
L-DOPA—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000233	0.00164	CcSEcCtD
L-DOPA—Vascular purpura—Prednisone—chronic obstructive pulmonary disease	0.000232	0.00163	CcSEcCtD
L-DOPA—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000231	0.00162	CcSEcCtD
L-DOPA—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000231	0.00162	CcSEcCtD
L-DOPA—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.00023	0.00162	CcSEcCtD
L-DOPA—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.00023	0.00162	CcSEcCtD
L-DOPA—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000229	0.00161	CcSEcCtD
L-DOPA—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000229	0.00161	CcSEcCtD
L-DOPA—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000228	0.0016	CcSEcCtD
L-DOPA—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000228	0.0016	CcSEcCtD
L-DOPA—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000228	0.0016	CcSEcCtD
L-DOPA—Dopamine—SLC6A4—chronic obstructive pulmonary disease	0.000228	0.0477	CrCbGaD
L-DOPA—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000227	0.0016	CcSEcCtD
L-DOPA—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000226	0.00159	CcSEcCtD
L-DOPA—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000225	0.00158	CcSEcCtD
L-DOPA—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000224	0.00158	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000224	0.00157	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000224	0.00157	CcSEcCtD
L-DOPA—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000223	0.00157	CcSEcCtD
L-DOPA—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000223	0.00157	CcSEcCtD
L-DOPA—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000223	0.00157	CcSEcCtD
L-DOPA—Norepinephrine—CYP1A2—chronic obstructive pulmonary disease	0.000223	0.0467	CrCbGaD
L-DOPA—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000221	0.00156	CcSEcCtD
L-DOPA—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000221	0.00156	CcSEcCtD
L-DOPA—Pain—Formoterol—chronic obstructive pulmonary disease	0.000221	0.00156	CcSEcCtD
L-DOPA—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000221	0.00156	CcSEcCtD
L-DOPA—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000221	0.00155	CcSEcCtD
L-DOPA—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.00022	0.00154	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000219	0.00154	CcSEcCtD
L-DOPA—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000219	0.00154	CcSEcCtD
L-DOPA—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000218	0.00153	CcSEcCtD
L-DOPA—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000217	0.00153	CcSEcCtD
L-DOPA—Pain—Montelukast—chronic obstructive pulmonary disease	0.000217	0.00152	CcSEcCtD
L-DOPA—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000217	0.00152	CcSEcCtD
L-DOPA—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000216	0.00152	CcSEcCtD
L-DOPA—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000216	0.00152	CcSEcCtD
L-DOPA—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000216	0.00152	CcSEcCtD
L-DOPA—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000215	0.00151	CcSEcCtD
L-DOPA—Purpura—Prednisone—chronic obstructive pulmonary disease	0.000215	0.00151	CcSEcCtD
L-DOPA—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000215	0.00151	CcSEcCtD
L-DOPA—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000214	0.00151	CcSEcCtD
L-DOPA—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000213	0.0015	CcSEcCtD
L-DOPA—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000213	0.0015	CcSEcCtD
L-DOPA—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000213	0.0015	CcSEcCtD
L-DOPA—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000213	0.00149	CcSEcCtD
L-DOPA—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000212	0.00149	CcSEcCtD
L-DOPA—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000212	0.00149	CcSEcCtD
L-DOPA—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000212	0.00149	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000211	0.00148	CcSEcCtD
L-DOPA—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000211	0.00148	CcSEcCtD
L-DOPA—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000209	0.00147	CcSEcCtD
L-DOPA—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000209	0.00147	CcSEcCtD
L-DOPA—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000207	0.00146	CcSEcCtD
L-DOPA—Dopamine—CYP1A2—chronic obstructive pulmonary disease	0.000207	0.0435	CrCbGaD
L-DOPA—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000207	0.00146	CcSEcCtD
L-DOPA—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000206	0.00145	CcSEcCtD
L-DOPA—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000206	0.00145	CcSEcCtD
L-DOPA—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000205	0.00144	CcSEcCtD
L-DOPA—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000205	0.00144	CcSEcCtD
L-DOPA—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000204	0.00143	CcSEcCtD
L-DOPA—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	0.000203	0.00142	CcSEcCtD
L-DOPA—Epinephrine—CYP1A2—chronic obstructive pulmonary disease	0.000202	0.0424	CrCbGaD
L-DOPA—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000202	0.00142	CcSEcCtD
L-DOPA—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000202	0.00142	CcSEcCtD
L-DOPA—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000202	0.00142	CcSEcCtD
L-DOPA—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000202	0.00142	CcSEcCtD
L-DOPA—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000202	0.00142	CcSEcCtD
L-DOPA—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000201	0.00141	CcSEcCtD
L-DOPA—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000201	0.00141	CcSEcCtD
L-DOPA—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.0002	0.00141	CcSEcCtD
L-DOPA—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000198	0.00139	CcSEcCtD
L-DOPA—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000197	0.00139	CcSEcCtD
L-DOPA—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000194	0.00137	CcSEcCtD
L-DOPA—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000193	0.00136	CcSEcCtD
L-DOPA—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000191	0.00134	CcSEcCtD
L-DOPA—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000191	0.00134	CcSEcCtD
L-DOPA—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000191	0.00134	CcSEcCtD
L-DOPA—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000187	0.00131	CcSEcCtD
L-DOPA—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000186	0.00131	CcSEcCtD
L-DOPA—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000186	0.00131	CcSEcCtD
L-DOPA—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000183	0.00129	CcSEcCtD
L-DOPA—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000183	0.00129	CcSEcCtD
L-DOPA—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000182	0.00128	CcSEcCtD
L-DOPA—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.00018	0.00127	CcSEcCtD
L-DOPA—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000179	0.00126	CcSEcCtD
L-DOPA—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000177	0.00125	CcSEcCtD
L-DOPA—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000177	0.00125	CcSEcCtD
L-DOPA—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000176	0.00124	CcSEcCtD
L-DOPA—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000175	0.00123	CcSEcCtD
L-DOPA—Liothyronine—ALB—chronic obstructive pulmonary disease	0.000175	0.0366	CrCbGaD
L-DOPA—Sweating increased—Prednisone—chronic obstructive pulmonary disease	0.000175	0.00123	CcSEcCtD
L-DOPA—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000174	0.00122	CcSEcCtD
L-DOPA—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000173	0.00122	CcSEcCtD
L-DOPA—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000171	0.0012	CcSEcCtD
L-DOPA—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000171	0.0012	CcSEcCtD
L-DOPA—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000168	0.00118	CcSEcCtD
L-DOPA—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000167	0.00118	CcSEcCtD
L-DOPA—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000165	0.00116	CcSEcCtD
L-DOPA—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000165	0.00116	CcSEcCtD
L-DOPA—Rash—Formoterol—chronic obstructive pulmonary disease	0.000163	0.00115	CcSEcCtD
L-DOPA—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000163	0.00115	CcSEcCtD
L-DOPA—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000163	0.00115	CcSEcCtD
L-DOPA—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000163	0.00115	CcSEcCtD
L-DOPA—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000163	0.00115	CcSEcCtD
L-DOPA—Headache—Formoterol—chronic obstructive pulmonary disease	0.000162	0.00114	CcSEcCtD
L-DOPA—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000162	0.00114	CcSEcCtD
L-DOPA—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000162	0.00114	CcSEcCtD
L-DOPA—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000162	0.00114	CcSEcCtD
L-DOPA—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000162	0.00114	CcSEcCtD
L-DOPA—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000161	0.00113	CcSEcCtD
L-DOPA—Rash—Montelukast—chronic obstructive pulmonary disease	0.00016	0.00112	CcSEcCtD
L-DOPA—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.00016	0.00112	CcSEcCtD
L-DOPA—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000159	0.00112	CcSEcCtD
L-DOPA—Depression—Prednisone—chronic obstructive pulmonary disease	0.000159	0.00112	CcSEcCtD
L-DOPA—Headache—Montelukast—chronic obstructive pulmonary disease	0.000159	0.00112	CcSEcCtD
L-DOPA—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000158	0.00111	CcSEcCtD
L-DOPA—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000157	0.0011	CcSEcCtD
L-DOPA—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000157	0.0011	CcSEcCtD
L-DOPA—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000157	0.0011	CcSEcCtD
L-DOPA—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000155	0.00109	CcSEcCtD
L-DOPA—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000155	0.00109	CcSEcCtD
L-DOPA—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000154	0.00108	CcSEcCtD
L-DOPA—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000154	0.00108	CcSEcCtD
L-DOPA—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000154	0.00108	CcSEcCtD
L-DOPA—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000154	0.00108	CcSEcCtD
L-DOPA—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000154	0.00108	CcSEcCtD
L-DOPA—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000153	0.00108	CcSEcCtD
L-DOPA—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000151	0.00106	CcSEcCtD
L-DOPA—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000151	0.00106	CcSEcCtD
L-DOPA—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000149	0.00105	CcSEcCtD
L-DOPA—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000148	0.00104	CcSEcCtD
L-DOPA—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000145	0.00102	CcSEcCtD
L-DOPA—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000145	0.00102	CcSEcCtD
L-DOPA—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000144	0.00101	CcSEcCtD
L-DOPA—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000143	0.00101	CcSEcCtD
L-DOPA—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000143	0.001	CcSEcCtD
L-DOPA—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.00014	0.000986	CcSEcCtD
L-DOPA—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000138	0.00097	CcSEcCtD
L-DOPA—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000136	0.000953	CcSEcCtD
L-DOPA—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000133	0.000936	CcSEcCtD
L-DOPA—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000128	0.000901	CcSEcCtD
L-DOPA—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000127	0.000892	CcSEcCtD
L-DOPA—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000127	0.000891	CcSEcCtD
L-DOPA—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000126	0.000885	CcSEcCtD
L-DOPA—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000126	0.000883	CcSEcCtD
L-DOPA—Pain—Prednisolone—chronic obstructive pulmonary disease	0.00012	0.000843	CcSEcCtD
L-DOPA—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000118	0.000827	CcSEcCtD
L-DOPA—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000116	0.000814	CcSEcCtD
L-DOPA—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000116	0.000812	CcSEcCtD
L-DOPA—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000115	0.000811	CcSEcCtD
L-DOPA—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000115	0.000807	CcSEcCtD
L-DOPA—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000114	0.000802	CcSEcCtD
L-DOPA—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000113	0.000792	CcSEcCtD
L-DOPA—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000112	0.000787	CcSEcCtD
L-DOPA—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000111	0.000783	CcSEcCtD
L-DOPA—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.00011	0.000772	CcSEcCtD
L-DOPA—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000761	CcSEcCtD
L-DOPA—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000758	CcSEcCtD
L-DOPA—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000745	CcSEcCtD
L-DOPA—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000738	CcSEcCtD
L-DOPA—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000103	0.000726	CcSEcCtD
L-DOPA—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000102	0.000716	CcSEcCtD
L-DOPA—Shock—Prednisone—chronic obstructive pulmonary disease	0.0001	0.000705	CcSEcCtD
L-DOPA—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	9.85e-05	0.000693	CcSEcCtD
L-DOPA—Anorexia—Prednisone—chronic obstructive pulmonary disease	9.72e-05	0.000683	CcSEcCtD
L-DOPA—Dizziness—Prednisolone—chronic obstructive pulmonary disease	9.28e-05	0.000652	CcSEcCtD
L-DOPA—Insomnia—Prednisone—chronic obstructive pulmonary disease	9.22e-05	0.000648	CcSEcCtD
L-DOPA—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	9.15e-05	0.000643	CcSEcCtD
L-DOPA—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	8.97e-05	0.000631	CcSEcCtD
L-DOPA—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	8.86e-05	0.000623	CcSEcCtD
L-DOPA—Rash—Prednisolone—chronic obstructive pulmonary disease	8.84e-05	0.000622	CcSEcCtD
L-DOPA—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	8.84e-05	0.000621	CcSEcCtD
L-DOPA—Fatigue—Prednisone—chronic obstructive pulmonary disease	8.79e-05	0.000618	CcSEcCtD
L-DOPA—Headache—Prednisolone—chronic obstructive pulmonary disease	8.79e-05	0.000618	CcSEcCtD
L-DOPA—Constipation—Prednisone—chronic obstructive pulmonary disease	8.72e-05	0.000613	CcSEcCtD
L-DOPA—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	8.4e-05	0.00059	CcSEcCtD
L-DOPA—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	8.34e-05	0.000586	CcSEcCtD
L-DOPA—Nausea—Prednisolone—chronic obstructive pulmonary disease	8.33e-05	0.000586	CcSEcCtD
L-DOPA—Urticaria—Prednisone—chronic obstructive pulmonary disease	8.1e-05	0.000569	CcSEcCtD
L-DOPA—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	8.06e-05	0.000566	CcSEcCtD
L-DOPA—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	7.51e-05	0.000528	CcSEcCtD
L-DOPA—Asthenia—Prednisone—chronic obstructive pulmonary disease	7.31e-05	0.000514	CcSEcCtD
L-DOPA—Pruritus—Prednisone—chronic obstructive pulmonary disease	7.21e-05	0.000507	CcSEcCtD
L-DOPA—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	6.97e-05	0.00049	CcSEcCtD
L-DOPA—Dizziness—Prednisone—chronic obstructive pulmonary disease	6.74e-05	0.000474	CcSEcCtD
L-DOPA—Vomiting—Prednisone—chronic obstructive pulmonary disease	6.48e-05	0.000456	CcSEcCtD
L-DOPA—Rash—Prednisone—chronic obstructive pulmonary disease	6.43e-05	0.000452	CcSEcCtD
L-DOPA—Dermatitis—Prednisone—chronic obstructive pulmonary disease	6.42e-05	0.000451	CcSEcCtD
L-DOPA—Headache—Prednisone—chronic obstructive pulmonary disease	6.39e-05	0.000449	CcSEcCtD
L-DOPA—Nausea—Prednisone—chronic obstructive pulmonary disease	6.05e-05	0.000426	CcSEcCtD
L-DOPA—DRD1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	5.74e-05	0.00103	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	5.7e-05	0.00102	CbGpPWpGaD
L-DOPA—PSIP1—Disease—NOS3—chronic obstructive pulmonary disease	5.69e-05	0.00102	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	5.66e-05	0.00101	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—VEGFA—chronic obstructive pulmonary disease	5.52e-05	0.000989	CbGpPWpGaD
L-DOPA—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	5.52e-05	0.000988	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	5.48e-05	0.00098	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	5.45e-05	0.000976	CbGpPWpGaD
L-DOPA—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	5.45e-05	0.000975	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	5.4e-05	0.000967	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—LEP—chronic obstructive pulmonary disease	5.27e-05	0.000943	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	5.27e-05	0.000943	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	5.21e-05	0.000932	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	5.21e-05	0.000932	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	5.2e-05	0.00093	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	5.14e-05	0.00092	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	5.14e-05	0.000919	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	5.13e-05	0.000918	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	5.09e-05	0.000912	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	5.09e-05	0.000911	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—TGFB1—chronic obstructive pulmonary disease	5.07e-05	0.000907	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	5.06e-05	0.000906	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	5.06e-05	0.000905	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	4.99e-05	0.000893	CbGpPWpGaD
L-DOPA—DDC—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.94e-05	0.000884	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—NOS2—chronic obstructive pulmonary disease	4.91e-05	0.000879	CbGpPWpGaD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	4.9e-05	0.000877	CbGpPWpGaD
L-DOPA—DDC—Metabolism—GCLC—chronic obstructive pulmonary disease	4.88e-05	0.000874	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—VEGFA—chronic obstructive pulmonary disease	4.82e-05	0.000863	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	4.66e-05	0.000835	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	4.64e-05	0.000831	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	4.63e-05	0.000829	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	4.62e-05	0.000827	CbGpPWpGaD
L-DOPA—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.61e-05	0.000824	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	4.59e-05	0.000821	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	4.56e-05	0.000816	CbGpPWpGaD
L-DOPA—DRD4—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	4.55e-05	0.000814	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	4.55e-05	0.000814	CbGpPWpGaD
L-DOPA—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.54e-05	0.000813	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	4.52e-05	0.00081	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	4.51e-05	0.000807	CbGpPWpGaD
L-DOPA—DDC—Metabolism—CTGF—chronic obstructive pulmonary disease	4.46e-05	0.000798	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	4.46e-05	0.000798	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—TGFB1—chronic obstructive pulmonary disease	4.42e-05	0.000792	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	4.36e-05	0.000781	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	4.33e-05	0.000775	CbGpPWpGaD
L-DOPA—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.23e-05	0.000757	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	4.2e-05	0.000751	CbGpPWpGaD
L-DOPA—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.17e-05	0.000747	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—TP53—chronic obstructive pulmonary disease	4.17e-05	0.000747	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	4.14e-05	0.000741	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	4.14e-05	0.00074	CbGpPWpGaD
L-DOPA—DDC—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.11e-05	0.000735	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	4.06e-05	0.000727	CbGpPWpGaD
L-DOPA—DRD3—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	4.04e-05	0.000723	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	4.02e-05	0.00072	CbGpPWpGaD
L-DOPA—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.01e-05	0.000718	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	4.01e-05	0.000718	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	4.01e-05	0.000717	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	3.98e-05	0.000712	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.96e-05	0.000709	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	3.96e-05	0.000708	CbGpPWpGaD
L-DOPA—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.96e-05	0.000708	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	3.93e-05	0.000704	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.9e-05	0.000698	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	3.87e-05	0.000693	CbGpPWpGaD
L-DOPA—PSIP1—Disease—TGFB1—chronic obstructive pulmonary disease	3.76e-05	0.000673	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.73e-05	0.000668	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.73e-05	0.000668	CbGpPWpGaD
L-DOPA—PSIP1—Disease—EGFR—chronic obstructive pulmonary disease	3.69e-05	0.00066	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—TP53—chronic obstructive pulmonary disease	3.64e-05	0.000652	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.62e-05	0.000647	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	3.54e-05	0.000634	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	3.49e-05	0.000625	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	3.46e-05	0.00062	CbGpPWpGaD
L-DOPA—DDC—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.43e-05	0.000613	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.42e-05	0.000612	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	3.41e-05	0.000611	CbGpPWpGaD
L-DOPA—DDC—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.38e-05	0.000605	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.25e-05	0.000582	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	3.23e-05	0.000578	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.22e-05	0.000577	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.21e-05	0.000575	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	3.17e-05	0.000567	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	3.16e-05	0.000566	CbGpPWpGaD
L-DOPA—DDC—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.15e-05	0.000563	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	3.13e-05	0.000559	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	3.1e-05	0.000555	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	3.09e-05	0.000553	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.08e-05	0.000551	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	3.07e-05	0.000549	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.04e-05	0.000543	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	3.03e-05	0.000542	CbGpPWpGaD
L-DOPA—DDC—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.98e-05	0.000534	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.93e-05	0.000524	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.9e-05	0.000519	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	2.89e-05	0.000518	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.88e-05	0.000515	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.86e-05	0.000512	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	2.85e-05	0.000509	CbGpPWpGaD
L-DOPA—PSIP1—Disease—IL6—chronic obstructive pulmonary disease	2.84e-05	0.000507	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	2.81e-05	0.000503	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.75e-05	0.000493	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.75e-05	0.000493	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.73e-05	0.000488	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.63e-05	0.000471	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.61e-05	0.000468	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	2.61e-05	0.000466	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.6e-05	0.000465	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.59e-05	0.000464	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	2.57e-05	0.00046	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.56e-05	0.000458	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.54e-05	0.000454	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.52e-05	0.000451	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.48e-05	0.000444	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.48e-05	0.000444	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.46e-05	0.00044	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.45e-05	0.000438	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.45e-05	0.000438	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.35e-05	0.000421	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.34e-05	0.000419	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.32e-05	0.000416	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.32e-05	0.000416	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.29e-05	0.000409	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.27e-05	0.000406	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.24e-05	0.0004	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.19e-05	0.000392	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	2.15e-05	0.000385	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.14e-05	0.000383	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	2.11e-05	0.000377	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	2.09e-05	0.000374	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	2.08e-05	0.000372	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.06e-05	0.000368	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.03e-05	0.000364	CbGpPWpGaD
L-DOPA—DDC—Metabolism—ALB—chronic obstructive pulmonary disease	2.03e-05	0.000363	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.01e-05	0.00036	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.99e-05	0.000356	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	1.97e-05	0.000352	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.96e-05	0.00035	CbGpPWpGaD
L-DOPA—DDC—Metabolism—NOS3—chronic obstructive pulmonary disease	1.94e-05	0.000347	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.93e-05	0.000346	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.91e-05	0.000343	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.9e-05	0.00034	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.87e-05	0.000335	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.87e-05	0.000335	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.87e-05	0.000335	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.83e-05	0.000328	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.81e-05	0.000325	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.79e-05	0.00032	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.78e-05	0.000318	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.73e-05	0.000309	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.71e-05	0.000306	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.7e-05	0.000305	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.69e-05	0.000302	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.66e-05	0.000298	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.56e-05	0.000278	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.56e-05	0.000278	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.55e-05	0.000278	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.54e-05	0.000276	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.54e-05	0.000275	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.41e-05	0.000253	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.4e-05	0.000251	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.4e-05	0.000251	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.4e-05	0.00025	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.39e-05	0.000249	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.38e-05	0.000247	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.37e-05	0.000245	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.37e-05	0.000245	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.35e-05	0.000242	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.34e-05	0.000239	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.27e-05	0.000228	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.27e-05	0.000228	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.27e-05	0.000228	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.26e-05	0.000226	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.26e-05	0.000225	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.26e-05	0.000225	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.25e-05	0.000223	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.22e-05	0.000218	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.2e-05	0.000215	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.17e-05	0.00021	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.14e-05	0.000203	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.13e-05	0.000202	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.13e-05	0.000202	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.12e-05	0.000201	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.12e-05	0.0002	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.08e-05	0.000192	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.06e-05	0.000189	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.05e-05	0.000188	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.03e-05	0.000185	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.02e-05	0.000183	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.02e-05	0.000183	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	9.86e-06	0.000176	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.6e-06	0.000172	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.54e-06	0.000171	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.44e-06	0.000169	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	9.41e-06	0.000168	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	9.3e-06	0.000166	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	9.18e-06	0.000164	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	9.18e-06	0.000164	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	9.17e-06	0.000164	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.87e-06	0.000159	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.75e-06	0.000157	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.54e-06	0.000153	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	8.47e-06	0.000152	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	8.43e-06	0.000151	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	8.36e-06	0.00015	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.35e-06	0.000149	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	8.27e-06	0.000148	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.94e-06	0.000142	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.88e-06	0.000141	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.77e-06	0.000139	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.55e-06	0.000135	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.51e-06	0.000134	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.41e-06	0.000133	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.24e-06	0.00013	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.14e-06	0.000128	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.05e-06	0.000126	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	7.02e-06	0.000126	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6.94e-06	0.000124	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.86e-06	0.000123	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.8e-06	0.000122	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.78e-06	0.000121	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.71e-06	0.00012	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.7e-06	0.00012	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.4e-06	0.000114	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL6—chronic obstructive pulmonary disease	6.35e-06	0.000114	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.22e-06	0.000111	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.1e-06	0.000109	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.1e-06	0.000109	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.02e-06	0.000108	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.67e-06	0.000102	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.6e-06	0.0001	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.53e-06	9.89e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.49e-06	9.83e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.42e-06	9.7e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.39e-06	9.65e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.13e-06	9.18e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.12e-06	9.17e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.69e-06	8.39e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	4.66e-06	8.35e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.61e-06	8.25e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.61e-06	8.25e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.55e-06	8.14e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	4.46e-06	7.98e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.23e-06	7.57e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.22e-06	7.55e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.16e-06	7.45e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.15e-06	7.42e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.48e-06	6.23e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.19e-06	5.7e-05	CbGpPWpGaD
